Nanosphere operates in the biotechnology sector, specializing in advanced multiplex antibody assays and clinical diagnostics. The company serves a diverse range of clients, including academic researchers, clinical laboratories, and biodefense organizations. Nanosphere's core technology offers exceptional sensitivity and specificity, unmatched throughput flexibility, and increased assay speed, making it highly valuable for infectious disease testing and other clinical applications. The business model revolves around selling its proprietary diagnostic systems and consumables, generating revenue through both direct sales and long-term service agreements. The company's open architecture design allows for a wide variety of applications, enhancing its market reach and adaptability.

Keywords: multiplex assays, clinical diagnostics, infectious disease, antibody screening, biodefense, academic research, assay speed, throughput flexibility, sensitivity, specificity.